BACKGROUND: @entity2175 ( @entity2175 ) is an @entity4903 that is characterized by chronic @entity4854 and tissue compartment abnormalities, including macrovascular and microvascular complications. More than 90% of @entity1 with @entity2175 will be diagnosed and treated in the primary care setting. One of the relatively recent additions to the increasing array of approved antidiabetic medications is the @entity5445 receptor agonist class. Mechanisms of action for @entity8142 agonists include: 1) stimulation of insulin secretion through b-cells, though only when @entity413 levels are elevated (hence, minimizing risk for @entity4053 ); 2) blunting of glucagon secretion; 3) increased satiety; and 4) decreased rate of release of gastric contents into the small intestine, thereby reducing glycemic load. Recent @entity2175 treatment guidelines encourage individualization of therapy. Many @entity1 still do not achieve optimal glycemic control. Therefore, other treatment options are important. METHODS: A literature search was performed using PubMed and MEDSCAPE to retrieve abstracts and articles pertinent to topics discussed in this review. Original research articles, reviews, and clinical trial manuscripts were identified based on relevance. Only English language articles were considered. Results In 3 phase 3 registration trials in @entity1 with @entity2175 , once-weekly dulaglutide demonstrated superior efficacy at the primary endpoint to @entity2449 as monotherapy, to @entity12350 as add-on to @entity2449 , and to exenatide twice daily as add-on to @entity2449 and @entity12098 . The safety profile of dulaglutide in these trials is similar to currently available @entity8142 agonists, characterized predominantly by @entity344 (ie, @entity390 , @entity391 , and @entity294 ). Based on these results, once-weekly dulaglutide should be a relevant additional treatment option for the management of @entity2175 .

Safety and efficacy of dulaglutide, a once weekly XXXX agonist, for the management of type 2 diabetes.

@entity2175 :: ('MESH:D003924', 'Disease') :: ['T2D', 'Type 2 diabetes'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity12098 :: ('MESH:C060836', 'Chemical') :: ['pioglitazone'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal symptoms'] @entity4903 :: ('MESH:D004700', 'Disease') :: ['increasingly common endocrine disorder'] @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia'] @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin'] @entity8142 :: ('2740', 'Gene') :: ['glucagon-like peptide-1 receptor'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide-1'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity8142 :: (2740,Gene) :: ['GLP-1 receptor']
